Use of loteprednol for routine prophylaxis after photorefractive keratectomy
Mark D Mifflin1, Lisa L Leishman1, Steven M Christiansen1, Shameema Sikder2, Maylon Hsu1, Majid Moshirfar11Department of Ophthalmology, John A Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, 2Wilmer Eye Institute, Johns Hopkins Hospital, Johns Hopkins University, Baltimo...
Guardado en:
Autores principales: | Moshirfar M, Hsu M, Sikder S, Christiansen SM, Mifflin MD, Leishman LL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a83f78ea50544c9fb98146d6c4e1f76a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
por: Mifflin MD, et al.
Publicado: (2017) -
A prospective, contralateral comparison of photorefractive keratectomy (PRK) versus thin-flap LASIK: assessment of visual function
por: Hatch BB, et al.
Publicado: (2011) -
Prospective, randomized, contralateral eye comparison of tetracaine and proparacaine for pain control in laser in situ keratomileusis and photorefractive keratectomy
por: Moshirfar M, et al.
Publicado: (2014) -
Use of angle kappa in myopic photorefractive keratectomy
por: Khakshoor H, et al.
Publicado: (2015) -
Prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave® Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations
por: Sikder S, et al.
Publicado: (2011)